Second market registration of Nescler for BioIntegrator

BioIntegrator, a member of the Russian ChemRar group of companies, announced today the successful launch in Belorussia of Nescler, a unique oral formulation of fingolimod, the blockbuster small molecule for treatment of remitting-relapsing multiple sclerosis marketed by Swiss pharma giant Novartis (NOVN: VX) as Gilenya.

Following the initial registration of Nescler in Russia in 2014, the drug has been gaining access to other emerging markets, with subsequent registrations planned in the countries of the Eurasian Economic Union (EAEU), Middle East and North Africa region (MENA) and the Association of Southeast Asian Nations (ASEAN).

The EAEU pharmaceutical market has been growing rapidly ever since due to the increase in average income, aging population and extensive government support. Currently, the EAEU pharmaceutical market is one of the most profitable markets in the region, with the Belorussian, Kazakh and Russian markets experiencing some of the highest growth rates among the emerging markets in the world.